Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nutra Pharma Corp. (NPHC : OTCBB)

• Company Description    Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company operates through its subsidiaries and carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma currently offers several drug products for sale for the treatment of pain: Cobroxin, the over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases. Nutra Pharma Corporation is based in Boca Raton, Florida. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 1,159,625 shares Shares Outstanding: 6,807.24 (millions) Market Capitalization: $8.17 (millions) Beta: 2.56 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.69% 3.97% 12 Week -36.84% -30.56% Year To Date -40.00% -26.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1537 NW 65th Ave - Plantation,FL 33313 USA ph: 954-509-0911 fax: 877-895-5647 investor.relations@nutrapharma.com http://www.nutrapharma.com

• General Corporate Information    Officers Rik J. Deitsch - Chairman; President and Chief Executive Office Garry R. Pottruck - Director Stewart Lonky - Director Harold Rumph - Director Dan Oran - Director Peer Information Nutra Pharma Corp. (CORR.) Nutra Pharma Corp. (RSPI) Nutra Pharma Corp. (CGXP) Nutra Pharma Corp. (BGEN) Nutra Pharma Corp. (GTBP) Nutra Pharma Corp. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67060U208 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/21 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 6,807.24 Most Recent Split Date: 5.00 (0.03:1) Beta: 2.56 Market Capitalization: $8.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 71.32% vs. Previous Quarter: 36.77% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - -1,940.15 09/30/21 - -3,106.21 Current Ratio 03/31/22 - - 12/31/21 - 0.03 09/30/21 - 0.02 Quick Ratio 03/31/22 - - 12/31/21 - 0.02 09/30/21 - 0.02 Operating Margin 03/31/22 - - 12/31/21 - -13,361.90 09/30/21 - -19,789.66 Net Margin 03/31/22 - - 12/31/21 - -13,361.90 09/30/21 - -19,789.66 Pre-Tax Margin 03/31/22 - - 12/31/21 - -13,399.50 09/30/21 - -19,789.66 Book Value 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Inventory Turnover 03/31/22 - - 12/31/21 - 3.49 09/30/21 - 2.57 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©